Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

This analysis from the phase II BRIGHT AML 1003 trial reports the long-term efficacy and safety of glasdegib + low-dose cytarabine (LDAC) in patients with acute myeloid leukemia ineligible for intensive chemotherapy. The multicenter, open-label study randomized (2:1) patients to receive glasdegib +...

Descripción completa

Detalles Bibliográficos
Autores principales: Heuser, Michael, Smith, B. Douglas, Fiedler, Walter, Sekeres, Mikkael A., Montesinos, Pau, Leber, Brian, Merchant, Akil, Papayannidis, Cristina, Pérez-Simón, José A., Hoang, Caroline J., O’Brien, Thomas, Ma, Weidong Wendy, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, Cortes, Jorge E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043884/
https://www.ncbi.nlm.nih.gov/pubmed/33740113
http://dx.doi.org/10.1007/s00277-021-04465-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043884/
https://www.ncbi.nlm.nih.gov/pubmed/33740113
http://dx.doi.org/10.1007/s00277-021-04465-4

Ejemplares similares